SL
TSHA icon

Siren LLC’s Taysha Gene Therapies TSHA Stock Holding History

Siren LLC’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$39.5M Sell
8,829,913
-1,300,000
-13% -$6.04M 1.09% 27
2025
Q4 		$55.7M Sell
10,129,913
-884,824
-8% -$4.3M 1.66% 20
2025
Q3 		$36M Hold
11,014,737
– – 1.41% 23
2025
Q2 		$25.4M Buy
11,014,737
+4,500,000
+69% +$9.78M 1.32% 23
2025
Q1 		$9.06M Sell
6,514,737
-87,738
-1% -$147K 0.51% 41
2024
Q4 		$11.4M Buy
6,602,475
+1,722,600
+35% +$3.57M 0.5% 44
2024
Q3 		$9.81M Buy
+4,879,875
New +$10.7M 0.49% 45

Other funds holding TSHA

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Siren LLC's TSHA Position: Q1 2026 in Review

Siren LLC reduced its Taysha Gene Therapies (TSHA) stake by 13% in Q1 2026, selling an estimated $6.04M and leaving 8,829,913 shares worth $39.5M. The position accounts for 1.09% of the portfolio, ranked #27.

Siren LLC first reported a position in TSHA in Q3 2024 and has held it in 7 quarters since. The position peaked at $55.7M in Q4 2025. 191 funds tracked by Wall St. Rank hold TSHA as of Q1 2026.

  • Siren LLC held 8,829,913 shares of Taysha Gene Therapies worth $39.5M as of Q1 2026.
  • Siren LLC sold 1,300,000 Taysha Gene Therapies shares in Q1 2026, an estimated $6.04M.
  • Taysha Gene Therapies made up 1.09% of Siren LLC's portfolio in Q1 2026, its #27 holding.
  • Siren LLC first reported a position in Taysha Gene Therapies in Q3 2024 and has held it in 7 quarters since.
  • Siren LLC's Taysha Gene Therapies position peaked at $55.7M in Q4 2025.
  • 191 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q1 2026.

Based on Siren LLC's 13F filing for Q1 2026, filed 14 May 2026.